Y MABS THERAPEUTICS ($YMAB) posted quarterly earnings results on Tuesday, May 13th. The company reported earnings of -$0.12 per share, beating estimates of -$0.21 by $0.09. The company also reported revenue of $20,900,000, beating estimates of $19,997,273 by $902,727.
You can see Quiver Quantitative's $YMAB stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
Y MABS THERAPEUTICS Insider Trading Activity
Y MABS THERAPEUTICS insiders have traded $YMAB stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $YMAB stock by insiders over the last 6 months:
- THOMAS GAD (CHIEF BUSINESS OFFICER) sold 10,810 shares for an estimated $56,536
- MICHAEL J ROSSI (PRESIDENT & CEO) sold 3,917 shares for an estimated $20,368
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Y MABS THERAPEUTICS Hedge Fund Activity
We have seen 50 institutional investors add shares of Y MABS THERAPEUTICS stock to their portfolio, and 55 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CORMORANT ASSET MANAGEMENT, LP removed 1,025,000 shares (-70.7%) from their portfolio in Q4 2024, for an estimated $8,025,750
- CALIGAN PARTNERS LP added 572,729 shares (+47.9%) to their portfolio in Q4 2024, for an estimated $4,484,468
- PICTET ASSET MANAGEMENT HOLDING SA removed 314,363 shares (-41.6%) from their portfolio in Q1 2025, for an estimated $1,392,628
- LOGOS GLOBAL MANAGEMENT LP added 200,000 shares (+25.0%) to their portfolio in Q4 2024, for an estimated $1,566,000
- D. E. SHAW & CO., INC. removed 172,405 shares (-21.9%) from their portfolio in Q4 2024, for an estimated $1,349,931
- PARADIGM BIOCAPITAL ADVISORS LP added 150,000 shares (+3.7%) to their portfolio in Q4 2024, for an estimated $1,174,500
- JPMORGAN CHASE & CO added 149,782 shares (+153.4%) to their portfolio in Q1 2025, for an estimated $663,534
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
